Isarna Therapeutics Stock

isarna-therapeutics.comHealthcareFounded: 1900Funding to Date: $131.24MM

Isarna Therapeutics is a clinical stage biotech company developing ISTH0036, a next-generation antisense to block TGF-beta 2 production, a key molecule in the pathogenesis of retinal disease.

Register for Details

For more details on financing and valuation for Isarna Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Isarna Therapeutics.

Register Today

Team

Management Team

Philippe Calais Ph.D
Chief Executive Officer
Karl-Hermann Schlingensiepen
Owner & Co-Founder

Other companies like Isarna Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B